PDF(Pubmed)
Abstract：
UNASSIGNED: Liver cancer due to hepatitis C (LCDHC) is one of the leading causes of cancer-related deaths worldwide, and the burden of LCDHC is increasing. We aimed to report the burden of LCDHC at the global, regional, and national levels in 204 countries from 1990 to 2019, stratified by etiology, sex, age, and Sociodemographic Index.
UNASSIGNED: Data on LCDHC were available from the Global Burden of Disease, Injuries, and Risk Factors (GBD) study 2019. Numbers and age-standardized mortality, incidence, and disability-adjusted life year (DALY) rates per 100,000 population were estimated through a systematic analysis of modeled data from the GBD 2019 study. The trends in the LCDHC burden were assessed using the annual percentage change.
UNASSIGNED: Globally, in 2019, there were 152,225 new cases, 141,810 deaths, and 2,878,024 DALYs due to LCDHC. From 1990 to 2019, the number of incidences, mortality, and DALY cases increased by 80.68%, 67.50%, and 37.20%, respectively. However, the age-standardized incidence, mortality, and DALY rate had a decreasing trend during this period. In 2019, the highest age-standardized incidence rates (ASIRs) of LCDHC were found in high-income Asia Pacific, North Africa and the Middle East, and Central Asia. At the regional level, Mongolia, Egypt, and Japan had the three highest ASIRs in 2019. The incidence rates of LCDHC were higher in men and increased with age, with a peak incidence in the 95+ age group for women and the 85-89 age group for men in 2019. A nonlinear association was found between the age-standardized rates of LCDHC and sociodemographic index values at the regional and national levels.
UNASSIGNED: Although the age-standardized rates of LCDHC have decreased, the absolute numbers of incident cases, deaths, and DALYs have increased, indicating that LCDHC remains a significant global burden. In addition, the burden of LCDHC varies geographically. Male and older adult/s individuals have a higher burden of LCDHC. Our findings provide insight into the global burden trend of LCDHC. Policymakers should establish appropriate methods to achieve the HCV elimination target by 2030 and reducing the burden of LCDHC.
UNASSIGNED: Data on LCDHC were available from the Global Burden of Disease, Injuries, and Risk Factors (GBD) study 2019. Numbers and age-standardized mortality, incidence, and disability-adjusted life year (DALY) rates per 100,000 population were estimated through a systematic analysis of modeled data from the GBD 2019 study. The trends in the LCDHC burden were assessed using the annual percentage change.
UNASSIGNED: Globally, in 2019, there were 152,225 new cases, 141,810 deaths, and 2,878,024 DALYs due to LCDHC. From 1990 to 2019, the number of incidences, mortality, and DALY cases increased by 80.68%, 67.50%, and 37.20%, respectively. However, the age-standardized incidence, mortality, and DALY rate had a decreasing trend during this period. In 2019, the highest age-standardized incidence rates (ASIRs) of LCDHC were found in high-income Asia Pacific, North Africa and the Middle East, and Central Asia. At the regional level, Mongolia, Egypt, and Japan had the three highest ASIRs in 2019. The incidence rates of LCDHC were higher in men and increased with age, with a peak incidence in the 95+ age group for women and the 85-89 age group for men in 2019. A nonlinear association was found between the age-standardized rates of LCDHC and sociodemographic index values at the regional and national levels.
UNASSIGNED: Although the age-standardized rates of LCDHC have decreased, the absolute numbers of incident cases, deaths, and DALYs have increased, indicating that LCDHC remains a significant global burden. In addition, the burden of LCDHC varies geographically. Male and older adult/s individuals have a higher burden of LCDHC. Our findings provide insight into the global burden trend of LCDHC. Policymakers should establish appropriate methods to achieve the HCV elimination target by 2030 and reducing the burden of LCDHC.
摘要：
丙型肝炎导致的肝癌（LCDHC）是全球癌症相关死亡的主要原因之一，LCDHC的负担正在增加。我们旨在报告LCDHC在全球的负担，区域,从1990年到2019年，204个国家的国家水平，按病因分层，性别,年龄,和社会人口指数。
■LCDHC的数据来自全球疾病负担，受伤,和2019年风险因素（GBD）研究。数字和年龄标准化死亡率，发病率,通过对GBD2019研究的建模数据进行系统分析，估计了每100,000人口的残疾调整生命年（DALY）率。使用年度百分比变化评估了LCDHC负担的趋势。
■全球，2019年，新增病例为152225例，141810人死亡,和2,878,024由于LCDHC的DALYs。从1990年到2019年，发病率、死亡率,DALY病例增加80.68%,67.50%,和37.20%，分别。然而,年龄标准化发病率，死亡率,在此期间，DALY率呈下降趋势。2019年，LCDHC的年龄标准化发病率(ASIR)最高的是高收入亚太地区，北非和中东，和中亚。在区域一级，蒙古,埃及,2019年，日本的ASIRs最高的三个。LCDHC在男性中的发病率较高，并且随着年龄的增长而增加，2019年女性95岁以上年龄组和男性85-89岁年龄组发病率最高。在区域和国家层面，LCDHC的年龄标准化率与社会人口统计学指数值之间存在非线性关联。
■尽管LCDHC的年龄标准化比率有所下降，事故案件的绝对数量，死亡,DALY增加了，表明LCDHC仍然是一个重大的全球负担。此外,LCDHC的负担在地理上有所不同。男性和老年人的LCDHC负担较高。我们的发现为LCDHC的全球负担趋势提供了见解。政策制定者应建立适当的方法，以实现到2030年消除HCV的目标，并减轻LCDHC的负担。
■LCDHC的数据来自全球疾病负担，受伤,和2019年风险因素（GBD）研究。数字和年龄标准化死亡率，发病率,通过对GBD2019研究的建模数据进行系统分析，估计了每100,000人口的残疾调整生命年（DALY）率。使用年度百分比变化评估了LCDHC负担的趋势。
■全球，2019年，新增病例为152225例，141810人死亡,和2,878,024由于LCDHC的DALYs。从1990年到2019年，发病率、死亡率,DALY病例增加80.68%,67.50%,和37.20%，分别。然而,年龄标准化发病率，死亡率,在此期间，DALY率呈下降趋势。2019年，LCDHC的年龄标准化发病率(ASIR)最高的是高收入亚太地区，北非和中东，和中亚。在区域一级，蒙古,埃及,2019年，日本的ASIRs最高的三个。LCDHC在男性中的发病率较高，并且随着年龄的增长而增加，2019年女性95岁以上年龄组和男性85-89岁年龄组发病率最高。在区域和国家层面，LCDHC的年龄标准化率与社会人口统计学指数值之间存在非线性关联。
■尽管LCDHC的年龄标准化比率有所下降，事故案件的绝对数量，死亡,DALY增加了，表明LCDHC仍然是一个重大的全球负担。此外,LCDHC的负担在地理上有所不同。男性和老年人的LCDHC负担较高。我们的发现为LCDHC的全球负担趋势提供了见解。政策制定者应建立适当的方法，以实现到2030年消除HCV的目标，并减轻LCDHC的负担。
